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1. Introduction
1.1. Epidemiology
Brain tumors are rare neoplasms, however, they represent the second commonest cancer in
childhood (the first being hemato-lymphoid neoplasms) and correspond to the main solid
tumor in the pediatric context (ages 0-19 years) [1]. In this setting, gliomas, and particularly
astrocytomas are the leading group. Pilocytic astrocytoma (PA) is the commonest brain tumor
in the ages 5-14 years and the second in the age ranges 0-4 years and 15-19 years, although it
represents about only 6% of all gliomas, according to the last Central Brain Tumors Registry
(CBTRUS) Report [1]. PA affects males and females equally, and the main affected ages are 6
to 13 years-old, with 75% of cases occurring at this ages [2; 3].
PAs present a good prognosis in general, with 10-year survival >90% [4]. However, about
10-20% of patients suffer with recurrence of completely excised lesions or growing of residual
lesions [4]. Besides, 2-3% of the cases may disseminate through the spinal cord [2; 4]. These
aggressive tumors are particularly more frequent in adults and older patients, which explains
the difference in the 10-year survival [5].Overall, the prognosis between children and adults
is significantly different [5]. While in children and young adults the 5-year survival is >90%,
in the group of 60+ years patients, this value is about 52% [5]. Likewise, the mortality rates
related to PAs are higher in adults than in children. Despite this could be explained by
differences in the location of these tumors in adults many evidences suggest that PA is in fact
a more aggressive neoplasm in older age groups [5].
© 2013 Paixao Becker et al.; licensee InTech. This is an open access article distributed under the terms of the
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unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. Anatomical location and neurorradiological features
The main location of PA is the cerebellum, with more than 60% of the cases occurring in
cerebellar hemispheres, however, it can arise all through the neuraxis, including hypothalamic
region, the optic-chiasmatic tract and spinal cord, with some cases involving the whole spinal
cord (“holocord pilocytic astrocytoma”) [2; 3; 6]- [9]. This wide distribution in the central
nervous system (CNS) may, in part, explain the differences in the prognosis of PA, since GTR
of a lesion located near or in eloquent areas of the CNS may be unachievable. In addition, some
locations present special features or are related to specific conditions. For example, multiple
tumors and tumors located in the optic-chiasmatic region are far more common in patients
with neurofibromatosis 1 (NF1), while supratentorial and spinal cord PAs are more frequent
in adults than in children [2; 5].
At neurorradiological exams, the typical finding is, generally, a non-infiltrative, well delimited
biphasic lesion, with a cystic, hipointense, area associated with a mural nodule, which can be
contrast-enhanced at magnetic resonance image (MRI) and computed tomography (CT),
however, diverse patterns as solid nodule or complete cystic lesions can be seen [2; 10] (Figure
1). In any case, perilesional edema is not commonly observed, as it is in high-grades primary
brain tumors [11]. Anecdotally, PA can be manifested as cerebral hemorrhage [12].
Figure 1. Neurorradiological features of Pilocytic Astrocytomas, after endovenous contrast injection. Note the absence
of perilesional edema, even in voluminous lesions. A- Cerebellar lesion – solid with cystic areas. This is the commonest
pattern of PA (MRI, coronal view). B- Cerebellar lesion, predominantly cystic with a mural nodule (CT, axial view). C-
solid, suprasselar lesion (MRI, coronal view).
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3. Clinical signs and symptoms
Due to its highly variable location in the neuraxis, the signs and symptoms of PA depend on
the affected area. As the most common location is the cerebellum, headache and neck pain,
vomiting, gait disturbance and visual abnormalities are usually referred [2; 3; 6; 13]. In
supratentorial tumors, the occurrence of seizures may be seen and is related to cortical
involvement [6]. In the hypothalamic area, PA may present with hormonal dysfunctions, for
example, diabetes insipidus, obesity [3; 11] and the diencephalic syndrome – emaciation,
hiperkinesis, irritability and accelerated growth [11]. The involvement of the optical pathway
is related to visual loss or visual-field deficits [6; 11]; proptosis presents only in large, intraor‐
bital tumors [6].
Clinical signs of intracranial hypertension, as hydrocephalus, papilledema, nistagmus, nausea
and vomiting are common in virtually all locations, because of the mass effect impinged by
the neoplasm [2; 3; 11]. On the other hand, smaller lesions may remain asymptomatic by some
variable time [11].
4. Histopathological aspects
Some histopathological features of PA are well-established, for instance, biphasic pattern, with
high- and low-cellularity areas; elongated (piloid) and rounded, oligodendroglial-like, cells
mixed in various proportions; microcystic areas; Rosenthal fibers, and eosinophilic granular
bodies are the commonest findings [2; 6] (Figure 2). In general, these findings support a
diagnosis of a low-grade astrocytoma (grade I), according to the World Health Organization
(WHO) criteria. However, features like microvascular proliferation, necrosis and degenerative
nuclear atypia, more commonly present in infiltrative, high-grade gliomas, may be seen
(Figure 3B, C). Diverse from infiltrative tumors, though, these features shall not be interpreted
as malignancy signs, unless they are associated to high mitotic activity [2; 3; 10]. Leptomenin‐
geal dissemination is quite common, and apparently is not related to aggressive behavior [14].
Calcification, hemorrhage and perivascular lymphocytic infiltration are less common (Figure
3A, D), but may be seen in some cases [10; 14]. Eventually, neuronal cells can be observed,
intermingled in the tumor, but they lack neoplastic features, and can be interpreted as
entrapped neurons [6; 10; 14].
Because of the great variation in histopathological appearance, the diagnosis of PA is usually
challenging, especially in minute biopsies, and greatly dependent upon correlation with
neurorradiological aspects [2; 3]. This can be such a dilemma, that some authors refer huge
discordance between pathologists, with half of PAs misdiagnosed as higher-grade tumors at
primary diagnosis [15].
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 Figure 2. Histopathological aspects of Pilocytic Astrocytoma. All microphotographs represent H&E stain. A- Biphasic
pattern – high cellularity at left and lower cellularity at bottom right (100x). B- Round and piloid cells constitute this
tumor. Note the vasculature, with typical endothelia (200x). C- Rosenthal fibers (black arrow) and eosinophilic granu‐
lar body (white arrow) can be seen in higher cellular areas (200x). D- At bottom, a microcystic area is seen (40x).
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Figure 3. Some other histopathological aspects of Pilocytic Astrocytoma at the H&E stain. A- Microvascular prolifera‐
tion (200x) B- Areas of necrosis may be seen in some tumors – in this case, the necrosis is at right (40x). C- Calcification
foci near a microcystic area of tumor (40x). D- Lymphocytic cuffs may be present (200x).
4.1. Differential diagnosis
Differential diagnoses of PA include low- and high-grade gliomas and the identification of
different entities has great importance in the treatment choice and prognosis of patients.
Among low-grade tumors, the most important differential diagnoses include ganglioglioma;
pleomorphic xantoastrocytoma (PXA); grade II oligodendroglioma; and diffuse astrocitoma.
In these cases, tumor location, neurorradiological and immunohistochemical features can help
in the definition, and this will be better discussed later in next sections. Moreover, hypothala‐
mic lesions, especially in infants, must also be distinguished from pilomixoid astrocytoma, a
recently described tumor, stated as grade II variant of PA in the last WHO classification [2; 3].
On the other hand, anaplastic astrocytoma and anaplastic oligodendroglioma (WHO grade
III) are some of the high grade lesions that can be confounded with PA [2; 3] when there are
degenerative atypia and/or oligodendroglial-like areas in the tumor. Finally, glioblastoma
(GBM – WHO grade IV), the commonest and most aggressive astrocytoma, share various
histological and neurorradiological features with PA, which makes the diagnosis problematic
in some cases [16]- [18]. In these cases, clinical correlation and immunohistochemical markers
can be used for better defining the diagnosis.
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5. Immunohistochemistry in the diagnosis of pylocitic astrocytoma
In order to reduce misdiagnoses, some immunohistochemical markers can be used to elucidate
complicated cases. There are no specific markers for PA, but differences between expressions
of standard antibodies can help in the task. Some of the main immunohistochemical markers
are described herein:
5.1. Glial Fibrillary Acidic Protein (GFAP)
GFAP is a cytoplasmatic intermediate filament, component of the cytoskeleton of normal and
neoplastic astrocytes [3]. Like in all astrocytomas, GFAP is persistently, diffusely expressed in
PAs, which does not permit the delineation between PA and diffuse astrocytomas. However,
it may be a useful tool to differentiate PA from other gliomas, such as ependymomas and
oligodendrogliomas.
As described earlier, some PAs may present perivascular lymphocytic cuffs and neuronal cells
entrapped among the neoplastic astrocytes. These characteristics are also seen in ganglioglio‐
mas [6]. To rule out this possibility, GFAP may help, as stated since 1970s by Eng and Rubin‐
stein [19], since the neoplastic neuronal cells in this tumor are negative and may be highlighted
in contrast to the strongly positive neoplastic astrocytes with this marker – this pattern
corroborates the mixed nature of ganglioglioma. There are other immunohistochemical
markers that help in this differential diagnosis, in addition to GFAP, for example, CD34
(positive in gangliogliomas and negative in PAs) and Neu N (neuronal marker, useful in the
identification of neoplastic and entrapped neurons).
Secondly, since PAs may present oligodendroglial-like areas and calcifications, another utility
for the use of GFAP is to differentiate these areas (in a small sample, for example) from
oligodendrogliomas. Oligodendroglial tumors are mostly negative, however, a peculiar
pattern of perinuclear immunoreactivity was recognized after the description of the proto‐
plasmatic oligodendrocytes, present in almost 80% of oligodendrogliomas [17; 20]. Even in
those positive cases, the pattern contrasts to the cytoplasmatic, diffuse positivity seen in the
PAs. Other immunohistochemical markers can be used in a panel in order to refine this
diagnosis, for instance, OLIG-2, a transcription factor involved in oligodendroglial differen‐
tiation [21]. Although some weak immunnopositivity may be seen in astrocytomas (low and
high grades) and more than 70% of PAs may be immunoreactive for OLIG-2 [22], according
to some authors, OLIG-2 can significantly distinguish oligodendroglial and astrocytic tumors
[20; 21]. As these both markers (GFAP and OLIG-2) can be simultaneously expressed by PAs
and oligodendrogliomas, the interpretation of these immunohistochemical tests must take in
account other histopathological findings and even neurorradiological features.
Finally, although GBM is a also a tumor of astrocytic lineage, it may present a different pattern
of GFAP immunopositivity. Opposed to the diffuse positivity in PA, GBM is heterogeneously
immunoreactive, predominant at the periphery of the tumor or only focal. This happens
because the immunoexpression of GFAP tends to decrease with the malignant progression of
astrocytomas [16; 17; 23].
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In summary, GFAP is an important marker of astrocytic differentiation and can help to
distinguish PA from other low- and high grade gliomas, both through the presence or absence
of its immunoexpression and the different patterns (subcellular location and distribution over
the tumor areas) of immunopositivity.
5.2. Ki67
The non-histone nuclear protein ki67 is a protein codified by genes present in the chromo‐
some 10 [24; 25]. It is expressed in the nuclei of cells in all but G0 and early G1 phases of
the  cellular  cycle  [26],  which allows a  faithful  estimative  of  the  proliferative  index of  a
neoplasm.  As  PA is  a  grade  I  astrocytoma,  low proliferative  index  is  the  rule  in  these
tumors [2; 3] (Figure 4A) with medium values about 2% [14; 27], however medium values
as high as 4,4% have been related [10; 28].
Figure 4. Immunnohistochemical aspects, with avidin-biotin-peroxidade technique. A- Ki67 – nuclear positivity in
about 2% of neoplastic cells(100x). B- Galectin-3 – this case showed weak, diffuse immunopositivity and predominant
cytoplasmatic location (100x). C- Galectin-3 strong, diffuse positivity and the vascular endothelium showed no reac‐
tion (100x). D- CD31 reaction in the endothelia – delicate vessels in the tumor (200x).
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Proliferative index by ki67 expression is a well established prognostic factor in diffuse
astrocytomas [29], yet, its role in the prognosis of PA is controversial. In 2002, Roessler et al
did not show significant differences between cerebellar PA when comparing groups according
to the proliferative index with a cut-off value of 5% [28] and this result was further corroborated
by other study with even lower cut-off value of 3% [10]. Shortly after, Bowers et al (2003)
described a subset of PA with worse prognosis, when the proliferative index determined by
Ki67 was >2% [27]. More recently higher medium values (>10%) were described in recurrent
and more aggressive PAs [10], and this exceptionally high value is similar to the medium value
of proliferative index for GBM (12,28%) described earlier by the same group [29].
Although the proliferative index is  still  a  questionable  independent  prognostic  factor  of
PAs, it is well accepted that a strict follow up is needed in the cases with high prolifera‐
tive activity [10; 27].
5.3. Galectin-3
Galectin-3 (gal-3) is a carbohydrate-binding protein that binds specifically to β-galactosides
sugars. This protein is involved in various biological processes, such as cellular proliferation,
apoptosis, transcriptional regulation, intracellular signalization, adhesion and migration [30;
31]. The expression of gal-3 may be seen in both cytoplasm and nuclei of neoplastic cells
(particularly carcinomas) from various organs, such as thyroid, pancreas and prostate [32], but
the relation between hyper- or loss of expression and biologic behavior of the tumor varies
among the different organs [32].
In APs, gal-3 is expressed in the nuclei and cytoplasm of neoplastic cells in all cases of PA
described by various authors [2; 10; 32; 33], but lacks the expression in the vascular endothe‐
lia(Figure 4B, C), contrary to what it is seen in non-neoplastic brain parenchyma [10; 33] and
in astrocytomas grades II and III and oligodendroglial tumors, which permits a faithful
delineation from PA when facing tough cases [17; 31].
Gal-3 is not specific of PA, since other low-grade tumors, such as ependymomas and PXA also
present diffuse expression of gal-3 [10; 32; 33]. Interestingly, focal (heterogenous) expression
of gal-3 is also seen in GBM [2; 18; 32], and although the vast differences between the biological
behavior and molecular pathways of these tumors, this expression may be related to micro‐
vascular proliferation and breaking of hematological barrier (and contrast-enhancement at
neuroimage) seen in these both entities [10; 18].
Although various studies have tried to relate the intensity and extension of gal-3 expression
to the clinical behavior of PA, no prognostic significance was proved until now. Still, as gal-3
expression is a conspicuous finding in PAs, in a pattern that can be differentiated from other
grades of astrocytoma, this marker may be very useful in the tumor diagnosis [10; 18; 32; 33].
Besides, recently a group of authors described a close relationship between expression of gal-3
and activation of the RAF-MEK-ERK pathway in pancreatic cancer [34] and, as we shall see
later in this chapter, that is an important molecular pathway in the genesis of PA, so gal-3 may
be soon proved as a potential target for future treatments.
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6. Molecular biology of pilocytic astrocytomas
Since no prognostic factors have been identified to differentiate regular from the more
aggressive Pas [5; 10; 14], the genetic characteristics of the PAs have recently been investigated
to better understand and try to predict the behavior of this tumor. Among these alterations,
chromossomal abnormalities (structural or numerical, as the aneuploidies), single-gene
mutations and epigenetic damage are mechanisms that could launch the molecular pathway
of oncogenesis.
The molecular pathways of oncogenesis differ in PAs and diffuse astrocytomas. For example,
two growth factor receptors, EGFR and PDGFR, related to invasion and malignant progres‐
sion, which are frequently hyperexpressed in infiltrative diffuse astrocytomas had a lower
expression in PAs observed by different groups [35; 36]. Besides, other genes characteristically
altered in diffuse gliomas, as TP53 and PTEN are normally expressed in Pas [2; 35; 37].
No cytogenetic abnormalities were detected in PA at first, and the majority of PAs presented
normal karyotype, similar to fetal astrocytes [37], and the majority of the altered tumors were
from female and adult patients [2]. Since then, a lot of genes have been investigated. We shall
see the most studied genes in PAs in the subsequent sessions.
6.1. NF1 gene
The first genetic studies tried to establish some differences between sporadic PAs and NF1-
PA, which present a more aggressive behaviour. It was known that NF1-PAs present germline
mutations of NF1 (in contrast to somatic mutations in GBM of this gene) and this results in a
loss of expression of the gene and, at protein level, results in a defective protein, neurofibromin
[3], which lastly permits a constitutive activation of the RAS-RAF-MERK-ERK molecular
pathway [4], or the mTOR/AKT pathway, activated in more aggressive Pas [4].
The detection of NF1 mutations can be achieved by molecular methods, by verifying the
expression of the gene or even at IHC, through the expression (or loss of expression) of
neurofibromin. [2; 3]
6.2. The RAS-RAF-MEK-ERK signaling pathway
The studies of NF1 gene were “the initial indication that Mitogen-activated protein kinase
(MAPK) signaling might play a role in the development of PAs”, as stated by Jones et al (2011)
[4]. Since then, various groups have investigated the participant proteins of these pathways.
The MAPK pathways regulate fundamental biologic processes. In mammalian, there are 4
well-described MAPK pathways [38; 39] (Figure 5) and the most studied is the extracellular
signal-regulated kinase (ERK)1/2 [39]. Alterations of this pathway are described in both low and
high-grade astrocytomas [4], but molecular mechanisms differ between them.
In  summary,  the  ERK1/2  pathway is  triggered  by  the  binding  of  soluble  peptides  to  a
Tyrosin-kinase  receptor  (TKR)  at  the  cell  surface,  and initiates  a  cascade  of  events  that
terminates in the appropriated cellular response [40].  This pathway is related to various
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fundamental  cellular  processes,  such  as  proliferation,  cellular  differentiation,  survival,
migration, and angiogenesis [41; 42].
The ERK cascade is constituted by RAS, Raf, MEK and ERK proteins [39], which are subse‐
quently activated during the process. After the binding of the extracellular peptide with the
TKR and its dimerization, it activates the RAS protein, which then activates the Raf family,
MEK and, finally, ERK protein [40; 43], that is present in the nuclei, to effectuate the response
to the.initiator sign [43]. The RAS-Raf league is considered the regulatory center of the ERK
cascade and mutations of any of this genes result in ERK pathway misregulation. It is important
to note that the mutations of these proteins are mutually exclusive [39].
The proteins of Raf family are the main effectors of RAS and their action is in phosphorylating
MEK 1 and MEK2 [44]. This family is a cytoplasmatic group of proteins, constituted by A-Raf,
B-Raf and C-Raf [43], proteins that present similar structure and biological features [44], although
they show different tissue distribution and capacity of activating the MEK proteins [45].
6.2.1. Oncogene BRAF
In humans, the most studied Raf protein is the B-Raf (BRAF), which is mutated in about 8% of
all human neoplasms [44], and in melanomas this rate can be as high as 60% of the cases, with
Figure 5. Integration of the MAPK pathways in the cellular response to various environmental stimuli. The sequential
phosphorilation of RAS-RAF-MEK ERK, after dimerization of TKR, and the role of negative regulation of NF1.
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the commonest mutation being point mutation V600E [46; 47].In the setting of PA, mutations
with constitutive activation of BRAF were demonstrated in up to 80% of cases, while they are
very rare in diffuse astrocytomas [48]. The mechanisms that explain a constitutive activation
of the BRAF are: i) point mutation V600E [44; 49; 50]; ii) duplication of a region in chromosome
7q [51; 52]; and iii) fusion between oncogenes BRAF and KIAA1549.
The point mutation V600E refers to a single glutamic acid for valin substitution at codon 600
of BRAF gene [44], which is the commonest BRAF missense mutation in human cancer [44;
46]. This mutation is not specific for PA and can be detected in various brain tumors, including
PXAs, gangliogliomas, and in up to 6% of GBMs [49; 50] and other tumors, such as thyroid
cancers and melanomas [44].
The BRAF duplications are due to a somatic rearrangement of the gene in sporadic PAs. It was
the first described genetic alteration of PAs [51; 52]. They are more frequent in gliomas in non-
cerebellar [52] location, including that of the optical pathways [53], both in NF1-related tumors
and in those sporadic ones. Nevertheless, other authors did not identify BRAF duplications in
NF1-related tumors, and suggested the activation of a different pathway (mTOR) in the genesis
of these frequently more aggressive tumors [54]
Finally, the fusion BRAF-KIAA1549 is present in 50-100% of the patients with PA [4; 55; 56].
This alteration is highly specific for PAs, and there is a growing tendency for using this marker
as a powerful tool of molecular diagnosis in surgical pathology routine [57]. Although this
fusion has recently been described in some other low-grade tumors, such as pilomixoid
astrocytoma, glioneuronal tumors and unclassifiable low grade gliomas [57; 58], clinical and
pathological correlation permit the diagnosis of PA in cases where diffuse component is
predominant at histology [57]. Also, this fusion is significantly more frequent in infratentorial
and optical pathways-located tumors [57].
The importance of studying the genetic mutations in PAs has grown, since many target
therapies  against  the  MAPKs  pathway  components  are  recently  being  developed.  For
example, concerning tumors with the V600E mutation, in 2012 two groups described the
use of Vemurafenib, a BRAF inhibitor, in melanoma [59] and in lung cancer [60], with good
results. In addition, other proteins of the ERK cascade can be targeted by novel drugs, as
Trametinib, a specific MEK inhibitor, that has also been used successfully in patients with
melanomas that present V600E mutation [61]. It is still unknown whether tumors harbor‐
ing the fusion BRAF-KIAA1549  are responsive to Vemurafenib and Trametinib. Concern‐
ing the former, the distinct studies showed the lack of patient’s response in the wildtype
BRAF [62]
At last, it is important to note that the resultant protein of the fusion BRAF-KIAA1549  is
cancer-specific  and it  is  potentially  a  target  for  future  treatments.  The  most  representa‐
tive  example  of  this  possibility  is  the  identification  of  the  fusion  BCR-ABL  in  chronic
myeloid leukemia (CML), in a similar molecular mechanism. The knowledge of this fusion
permitted the development of a target-drug, Imatinib, in the middle 2000´s [63].This drug
has changed the treatment and prognosis of the CML patients by controlling the disease,
with excellent tolerability.
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The molecular pathways of PAs are beginning to be faithfully recognized and some of the
molecules of these pathways have already some kind of target drug available for inhibition,
with efficacy proved in other kinds of tumors. As there are no studies with these novel drugs
in PAs, this can become a good direction for future clinical research.
7. Conclusion
Pilocytic astrocytoma is usually a tumor with good prognosis; however some eloquent
locations do not permit the total resection of lesions. In these cases and in the ones that can
recur even after gross total resection, the patients can suffer with physical limitations and even
death. The study of the molecular pathways of PA´s oncogenesis may represent a hope for
longer and better quality life for these patients. There is a wide field for research in order to
better understand this intriguing tumor, since the understanding of these mechanisms can turn
a potentially fatal in a controllable disease.
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